請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58530完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 張國柱 | |
| dc.contributor.author | En-Ting Wu | en |
| dc.contributor.author | 吳恩婷 | zh_TW |
| dc.date.accessioned | 2021-06-16T08:18:42Z | - |
| dc.date.available | 2014-02-25 | |
| dc.date.copyright | 2014-02-25 | |
| dc.date.issued | 2014 | |
| dc.date.submitted | 2014-02-10 | |
| dc.identifier.citation | Ahmad S, Shahab U, Baig MH, Khan MS, Srivastava AK, Saeed M & Moinuddin (2013) Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products. PLoS One 8, e72128.
Aronson D (2003) Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 21, 3-12. Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA & Oparil S (2004) Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 17, 23S-30S. Barile GR & Schmidt AM (2007) RAGE and its ligands in retinal disease. Curr Mol Med 7, 758-765. Baynes JW & Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48, 1-9. Booth AA, Khalifah RG & Hudson BG (1996) Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun 220, 113-119. Booth AA, Khalifah RG, Todd P & Hudson BG (1997) In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J Biol Chem 272, 5430-5437. Brock JW, Hinton DJ, Cotham WE, Metz TO, Thorpe SR, Baynes JW & Ames JM (2003) Proteomic analysis of the site specificity of glycation and carboxymethylation of ribonuclease. J Proteome Res 2, 506-513. Brownlee M, Vlassara H & Cerami A (1985) Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 34, 938-941. Bucala R & Cerami A (1992) Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 23, 1-34. Bunag RD, Krizsan D & Eriksson L (1990) Mediation of reflex tachycardia becomes exclusively beta-adrenergic in old Fischer 344 rats. Mech Ageing Dev 52, 179-194. Burattini R, Fioretti S & Jetto L (1985) A simple algorithm for defining the mean cardiac cycle of aortic flow and pressure during steady state. Comput Biomed Res 18, 303-312. Cantini C, Kieffer P, Corman B, Liminana P, Atkinson J & Lartaud-Idjouadiene I (2001) Aminoguanidine and aortic wall mechanics, structure, and composition in aged rats. Hypertension 38, 943-948. Cefalu WT, Bell-Farrow AD, Wang ZQ, Sonntag WE, Fu MX, Baynes JW & Thorpe SR (1995) Caloric restriction decreases age-dependent accumulation of the glycoxidation products, N epsilon-(carboxymethyl)lysine and pentosidine, in rat skin collagen. J Gerontol A Biol Sci Med Sci 50, B337-341. Chang KC, Chow CY, Peng YI, Chen TJ & Tsai YF (1999) Effects of food restriction on mechanical properties of arterial system in adult and middle-aged rats. J Gerontol A Biol Sci Med Sci 54, B441-447. Chang KC, Hsu KL, Peng YI, Lee FC & Tseng YZ (2003a) Aminoguanidine prevents age-related aortic stiffening in Fisher 344 rats: aortic impedance analysis. Br J Pharmacol 140, 107-114. Chang KC, Hsu KL & Tseng YZ (2003b) Effects of diabetes and gender on mechanical properties of the arterial system in rats: aortic impedance analysis. Exp Biol Med (Maywood) 228, 70-78. Chang KC, Liang JT, Tsai PS, Wu MS & Hsu KL (2009) Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen. Br J Pharmacol 157, 1419-1426. Chang KC, Liang JT, Tseng CD, Wu ET, Hsu KL, Wu MS, Lin YT & Tseng YZ (2007) Aminoguanidine prevents fructose-induced deterioration in left ventricular-arterial coupling in Wistar rats. Br J Pharmacol 151, 341-346. Chang KC, Peng YI, Dai SH & Tseng YZ (2000) Age-related changes in pumping mechanical behavior of rat ventricle in terms of systolic elastance and resistance. J Gerontol A Biol Sci Med Sci 55, B440-447. Chang KC, Peng YI, Lee FC & Tseng YZ (2001) Effects of food restriction on systolic mechanical behavior of the ventricular pump in middle-aged and senescent rats. J Gerontol A Biol Sci Med Sci 56, B108-114. Chen CH, Ting CT, Nussbacher A, Nevo E, Kass DA, Pak P, Wang SP, Chang MS & Yin FC (1996) Validation of carotid artery tonometry as a means of estimating augmentation index of ascending aortic pressure. Hypertension 27, 168-175. Chen J, Brodsky SV, Goligorsky DM, Hampel DJ, Li H, Gross SS & Goligorsky MS (2002) Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells. Circ Res 90, 1290-1298. Coleman GL, Barthold W, Osbaldiston GW, Foster SJ & Jonas AM (1977) Pathological changes during aging in barrier-reared Fischer 344 male rats. J Gerontol 32, 258-278. Corman B, Duriez M, Poitevin P, Heudes D, Bruneval P, Tedgui A & Levy BI (1998) Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc Natl Acad Sci U S A 95, 1301-1306. Covell JW, Ross J, Jr., Sonnenblick EH & Braunwald E (1966) Comparison of the force-velocity relation and the ventricular function curve as measures of the contractile state of the intact heart. Circ Res 19, 364-372. Cox RH (1974) Three-dimensional mechanics of arterial segments in vitro: methods. J Appl Physiol 36, 381-384. Cox RH (1983) Age-related changes in arterial wall mechanics and composition of NIA Fischer rats. Mech Ageing Dev 23, 21-36. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR & Baynes JW (2002) Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61, 939-950. Degenhardt TP, Thorpe SR & Baynes JW (1998) Chemical modification of proteins by methylglyoxal. Cell Mol Biol (Noisy-le-grand) 44, 1139-1145. Del Turco S & Basta G (2012) An update on advanced glycation endproducts and atherosclerosis. Biofactors 38, 266-274. Delp MD, Evans MV & Duan C (1998) Effects of aging on cardiac output, regional blood flow, and body composition in Fischer-344 rats. J Appl Physiol 85, 1813-1822. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR & Baynes JW (1993) Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91, 2463-2469. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, Wagle D, Jerums G & Cooper ME (2001) Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44, 108-114. Fukami K, Yamagishi SI & Okuda S (2013) Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des. Glomb MA & Monnier VM (1995) Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 270, 10017-10026. Goldin A, Beckman JA, Schmidt AM & Creager MA (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114, 597-605. Greenwald SE (2007) Ageing of the conduit arteries. J Pathol 211, 157-172. Hudson BI, Bucciarelli LG, Wendt T, Sakaguchi T, Lalla E, Qu W, Lu Y, Lee L, Stern DM, Naka Y, Ramasamy R, Yan SD, Yan SF, D'Agati V & Schmidt AM (2003) Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys 419, 80-88. Jain SK (2007) Vitamin B6 (pyridoxamine) supplementation and complications of diabetes. Metabolism 56, 168-171. Jain SK & Lim G (2001) Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes. Free Radic Biol Med 30, 232-237. Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, Takahashi H, Hirawa N, Oogushi Y, Miyata T, Kobayashi H, Fukagawa M & Saito A Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 57, 422-431. Kalea AZ, Schmidt AM & Hudson BI (2009) RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) 116, 621-637. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC & Lakatta EG (2001) Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104, 1464-1470. Kerkeni M, Saidi A, Bouzidi H, Letaief A, Ben Yahia S & Hammami M (2012) Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diab Vasc Dis Res 10, 239-245. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K & Vlassara H (1997) Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94, 6474-6479. Lakatta EG (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 107, 490-497. Lakatta EG & Levy D (2003a) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a 'set up' for vascular disease. Circulation 107, 139-146. Lakatta EG & Levy D (2003b) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation 107, 346-354. Laxminarayan S, Sipkema P & Westerhof N (1978) Characterization of the arterial system in the time domain. IEEE Trans Biomed Eng 25, 177-184. Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK & Lewis JB (2012) Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 23, 131-136. Li YM, Steffes M, Donnelly T, Liu C, Fuh H, Basgen J, Bucala R & Vlassara H (1996) Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci U S A 93, 3902-3907. Lingelbach LB, Mitchell AE, Rucker RB & McDonald RB (2000) Accumulation of advanced glycation endproducts in aging male Fischer 344 rats during long-term feeding of various dietary carbohydrates. J Nutr 130, 1247-1255. Liu Z, Brin KP & Yin FC (1986) Estimation of total arterial compliance: an improved method and evaluation of current methods. Am J Physiol 251, H588-600. Makita Z, Vlassara H, Cerami A & Bucala R (1992) Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267, 5133-5138. Mallipattu SK, He JC & Uribarri J (2012) Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients. Semin Dial 25, 529-538. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW & Lyons TJ (1993) Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91, 2470-2478. Metz TO, Alderson NL, Chachich ME, Thorpe SR & Baynes JW (2003) Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem 278, 42012-42019. Milnor WR (1975) Arterial impedance as ventricular afterload. Circ Res 36, 565-570. Mitchell GF, Pfeffer MA, Westerhof N & Pfeffer JM (1994) Measurement of aortic input impedance in rats. Am J Physiol 267, H1907-1915. Monnier VM, Kohn RR & Cerami A (1984) Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci U S A 81, 583-587. Myint KM, Yamamoto Y, Doi T, Kato I, Harashima A, Yonekura H, Watanabe T, Shinohara H, Takeuchi M, Tsuneyama K, Hashimoto N, Asano M, Takasawa S, Okamoto H & Yamamoto H (2006) RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 55, 2510-2522. Nass N, Bartling B, Navarrete Santos A, Scheubel RJ, Borgermann J, Silber RE & Simm A (2007) Advanced glycation end products, diabetes and ageing. Z Gerontol Geriatr 40, 349-356. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D & Shaw A (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267, 14998-15004. Nicholl ID & Bucala R (1998) Advanced glycation endproducts and cigarette smoking. Cell Mol Biol (Noisy-le-grand) 44, 1025-1033. Nicholl ID, Stitt AW, Moore JE, Ritchie AJ, Archer DB & Bucala R (1998) Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers. Mol Med 4, 594-601. Nichols WW (2005) Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 18, 3S-10S. Nichols WW, Conti CR, Walker WE & Milnor WR (1977) Input impedance of the systemic circulation in man. Circ Res 40, 451-458. Nichols WW, O'Rourke MF, Avolio AP, Yaginuma T, Murgo JP, Pepine CJ & Conti CR (1985) Effects of age on ventricular-vascular coupling. Am J Cardiol 55, 1179-1184. Nichols WW & Pepine CJ (1982) Left ventricular afterload and aortic input impedance: implications of pulsatile blood flow. Prog Cardiovasc Dis 24, 293-306. O'Rourke MF & Nichols WW (2005) Aortic diameter, aortic stiffness, and wave reflection increase with age and isolated systolic hypertension. Hypertension 45, 652-658. O'Rourke MF, Nichols WW & O'Brien E (2005) Effects of ramipril on arterial stiffness. Hypertension 46, e14; author reply e14-15. Padival S & Nagaraj RH (2006) Pyridoxamine inhibits maillard reactions in diabetic rat lenses. Ophthalmic Res 38, 294-302. Pepine CJ & Nichols WW (1982) Aortic input impedance in cardiovascular disease. Prog Cardiovasc Dis 24, 307-318. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR & Baynes JW (1995) N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34, 10872-10878. Reiser KM (1991) Nonenzymatic glycation of collagen in aging and diabetes. Proc Soc Exp Biol Med 196, 17-29. Sarma PS, Snell EE & Elvehjem CA (1946) The vitamin B6 group; biological assay of pyridoxal, pyridoxamine, and pyridoxine. J Biol Chem 165, 55-63. Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD, Brett J, Cao R, Kuwabara K, Costache G & et al. (1994a) Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A 91, 8807-8811. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL & Stern D (1994b) Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 14, 1521-1528. Schulman SP, Lakatta EG, Fleg JL, Lakatta L, Becker LC & Gerstenblith G (1992) Age-related decline in left ventricular filling at rest and exercise. Am J Physiol 263, H1932-1938. Singh R, Barden A, Mori T & Beilin L (2001) Advanced glycation end-products: a review. Diabetologia 44, 129-146. Sipkema P, Westerhof N & Randall OS (1980) The arterial system characterised in the time domain. Cardiovasc Res 14, 270-279. Smith DL, Jr., Elam CF, Jr., Mattison JA, Lane MA, Roth GS, Ingram DK & Allison DB (2010) Metformin supplementation and life span in Fischer-344 rats. J Gerontol A Biol Sci Med Sci 65, 468-474. Suji G & Sivakami S (2006) DNA damage by free radical production by aminoguanidine. Ann N Y Acad Sci 1067, 191-199. Takatori A, Ishii Y, Itagaki S, Kyuwa S & Yoshikawa Y (2004) Amelioration of the beta-cell dysfunction in diabetic APA hamsters by antioxidants and AGE inhibitor treatments. Diabetes Metab Res Rev 20, 211-218. Takeda T (1999) Senescence-accelerated mouse (SAM): a biogerontological resource in aging research. Neurobiol Aging 20, 105-110. Takeda T, Hosokawa M & Higuchi K (1991) Senescence-accelerated mouse (SAM): a novel murine model of accelerated senescence. J Am Geriatr Soc 39, 911-919. Tanimoto M, Gohda T, Kaneko S, Hagiwara S, Murakoshi M, Aoki T, Yamada K, Ito T, Matsumoto M, Horikoshi S & Tomino Y (2007) Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism 56, 160-167. Turk Z, Misur I, Turk N & Benko B (1999) Rat tissue collagen modified by advanced glycation: correlation with duration of diabetes and glycemic control. Clin Chem Lab Med 37, 813-820. Turturro A, Witt WW, Lewis S, Hass BS, Lipman RD & Hart RW (1999) Growth curves and survival characteristics of the animals used in the Biomarkers of Aging Program. J Gerontol A Biol Sci Med Sci 54, B492-501. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K & Cerami A (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A 91, 4766-4770. Vlassara H (1994) Recent progress on the biologic and clinical significance of advanced glycosylation end products. J Lab Clin Med 124, 19-30. Vlassara H, Bucala R & Striker L (1994a) Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70, 138-151. Vlassara H, Cai W, Goodman S, Pyzik R, Yong A, Chen X, Zhu L, Neade T, Beeri M, Silverman JM, Ferrucci L, Tansman L, Striker GE & Uribarri J (2009) Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 94, 4483-4491. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM & Steffes M (1994b) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 91, 11704-11708. Vlassara H & Uribarri J (2004) Glycoxidation and diabetic complications: modern lessons and a warning? Rev Endocr Metab Disord 5, 181-188. Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, Grosjean F, Woodward M & Striker GE Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol 7, 934-942. Voziyan PA, Metz TO, Baynes JW & Hudson BG (2002) A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 277, 3397-3403. Walker EM, Jr., Nillas MS, Mangiarua EI, Cansino S, Morrison RG, Perdue RR, Triest WE, Wright GL, Studeny M, Wehner P, Rice KM & Blough ER (2006) Age-associated changes in hearts of male Fischer 344/Brown Norway F1 rats. Ann Clin Lab Sci 36, 427-438. Westerhof N, Sipkema P, van den Bos GC & Elzinga G (1972) Forward and backward waves in the arterial system. Cardiovasc Res 6, 648-656. Wilkinson-Berka JL, Kelly DJ, Koerner SM, Jaworski K, Davis B, Thallas V & Cooper ME (2002) ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 51, 3283-3289. Williams ME (2004) Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Curr Diab Rep 4, 441-446. Wolff SP & Dean RT (1987) Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J 245, 243-250. Wong LS, Oeseburg H, de Boer RA, van Gilst WH, van Veldhuisen DJ & van der Harst P (2009) Telomere biology in cardiovascular disease: the TERC-/- mouse as a model for heart failure and ageing. Cardiovasc Res 81, 244-252. Wu ET, Liang JT, Wu MS & Chang KC Pyridoxamine prevents age-related aortic stiffening and vascular resistance in association with reduced collagen glycation. Exp Gerontol 46, 482-488. Wu MS, Liang JT, Lin YD, Wu ET, Tseng YZ & Chang KC (2008) Aminoguanidine prevents the impairment of cardiac pumping mechanics in rats with streptozotocin and nicotinamide-induced type 2 diabetes. Br J Pharmacol 154, 758-764. Yamamoto H, Watanabe T, Yamamoto Y, Yonekura H, Munesue S, Harashima A, Ooe K, Hossain S, Saito H & Murakami N (2007) RAGE in diabetic nephropathy. Curr Mol Med 7, 752-757. Yan SF, Barile GR, D'Agati V, Du Yan S, Ramasamy R & Schmidt AM (2007) The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications. Curr Diab Rep 7, 146-153. Yan SF, Ramasamy R, Naka Y & Schmidt AM (2003) Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93, 1159-1169. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE & Striker LJ (1994) Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 91, 9436-9440. Yu BP, Masoro EJ & McMahan CA (1985) Nutritional influences on aging of Fischer 344 rats: I. Physical, metabolic, and longevity characteristics. J Gerontol 40, 657-670. Zieman SJ, Kamineni A, Ix JH, Barzilay J, Djousse L, Kizer JR, Biggs ML, de Boer IH, Chonchol M, Gottdiener JS, Selvin E, Newman AB, Kuller LH, Siscovick DS & Mukamal KJ (2012) Hemoglobin A1c and arterial and ventricular stiffness in older adults. PLoS One 7, e47941. Zieman SJ & Kass DA (2004) Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 64, 459-470. Zieman SJ, Melenovsky V & Kass DA (2005) Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 25, 932-943. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58530 | - |
| dc.description.abstract | 老化引起許多心血管變化，包括高血壓、血管硬化、心肌肥厚等。其中的作用機轉很多，本論文主要是針對高度醣化終產物 (advanced glycation end products, AGE) 和老化血管的關係，因高度醣化終產物與高度脂氧化終產物 (advanced lipoxidation end products, ALE) 而導致組織內蛋白質氧化性化學修飾增加，已知與正常老化有關。有許多物質可能可以阻擋 AGE/ALE 的後續反應，Pyridoxamine (PM) 是其中一種。 PM 為三種自然形式的維生素 B6 之一，已確認能夠抑制碳水化合物的自氧化作用和脂質的過氧化作用所產生的 AGE/ALE。 本試驗旨在探討 PM 介入是否能抑制醣化膠原蛋白的病理性交聯作用 (cross-linking)，而預防老年主動脈硬化及血管阻抗的上升。
本實驗中，我們使用 15 月齡的雄性 Fisher 344 大鼠，每日給予 PM (1 g l-1，加入飲水中) 共五個月，於 20 月齡時與同齡、未用藥的控制組比較，同時也和六個月大的大鼠來做比較以證實老化在大鼠的心血管影響。我們測定脈衝式主動脈壓與血流訊號，接著用於血管阻抗分析。此外，採用蛋白質點漬分析法，以 AGE 抗體 6D12 偵測主動脈膠原蛋白上因醣化作用所產生的修飾作用。我們發現 PM 治療減緩了周邊血管總阻力因年齡而增加的情形。PM 促使波傳輸時間及主動脈容積增加，顯示 PM 能夠增進老化血管組織的主動脈擴張度，同時也減低主動脈上 AGE 與膠原蛋白的交聯作用。波傳輸時間增加，波反射係數減低，也顯示老年動物的 PM 治療能夠預防心臟血流負荷因老化而加重。這些發現顯示，老年大鼠使用 PM 後，能夠減少主動脈上 AGE 與膠原蛋白的病理性的交聯作用，有助於改善動脈力學。 | zh_TW |
| dc.description.abstract | An increase in oxidative chemical modifications of tissue proteins by advanced glycation end products (AGEs) and advanced lipoxidation end products (ALEs) has been implicated in normal aging. Pyridoxamine (PM), one of the three natural forms of vitamin B6, has been identified as an inhibitor of AGE/ALE products formed
during the autoxidation of carbohydrates and peroxidation of lipids. The current study seeks to determine whether PM intervention could prevent the age-related aortic stiffening and vascular resistance through its ability to inhibit the pathogenic cross-linking of glycated collagen. Male Fisher 344 rats at 15 months were treated daily with PM (1 g l−1 in drinking water) for 5 months and compared with the age-matched, untreated controls at 20 months. Pulsatile aortic pressure and flow signals were measured to perform the vascular impedance analysis. The anti-AGE antibody 6D12 was used to detect glycation-derived modification of aortic collagen, using protein blotting analysis. PM therapy attenuated the age-related increase in total peripheral resistance. An increase in wave transit time and aortic compliance by PM indicated that the drug improved aortic distensibility of the aged vasculature. This paralleled its reduction of AGE-collagen cross-links on aortas. Treatment of the old animals with PM also prevented the age-induced augmentation in vascular load imposed on the heart, as evidenced by an increased wave transit time and a decreased wave reflection factor. These findings suggest a partial role of PM in improving arterial mechanics by targeting the pathogenic formation of AGE-induced aortic collagen cross-links in old rats. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T08:18:42Z (GMT). No. of bitstreams: 1 ntu-103-D92441005-1.pdf: 9986976 bytes, checksum: 4ba7f0c39934960e4ede0fb91bfb8acb (MD5) Previous issue date: 2014 | en |
| dc.description.tableofcontents | 口試委員會審定書 i
致謝 ii 縮寫名詞對照表 iii 中文摘要 vi 英文摘要 viii 一、前言 1 (一) 老化的趨勢 1 (二) 老化的心血管變化 1 (三) 高度醣化終產物 (AGE) 和心血管變化的關係 3 1. 高度醣化終產物 (Advance Glycation End Products, AGE) 的形成 3 ( 1 ) 非酵素糖化反應路徑 (nonenzymatic glycation pathway) 4 ( 2 ) -oxocarbonyls 的形成 5 ( 3 ) 氧化壓力增加 6 ( 4 ) 來自體外的AGEs 8 2. AGEs 導致動脈硬化 9 ( 1 ) 使細胞外長生型蛋白質間形成交叉連結 (cross link) 9 ( 2 ) 與細胞膜上的AGEs 受器 (receptors) 結合 10 (四) 抑制 AGE 形成的物質 12 (五) Pyridoxamine (PM) 對 AGE 的作用 14 1. 抑制 Amadori products 後續形成 AGEs 的反應 14 2. 清除多種有害的α-oxocarbonyls 15 3. 抑制ROS形成 15 二、實驗方法 18 (一) 實驗動物 18 (二) 實驗儀器 18 2. 電磁感應血流計 (electromagnetic flowmeter) 19 (三) 動脈物理，性質之量化 20 1. 心血管功能的評估指標 20 2. 主動脈輸入阻抗頻譜的特性及功能 21 (三) 研究方法 22 1. 動物實驗與導管置放 22 2. 資料轉換和分析方法 24 ( 1 ) 平均周期運算法則(mean cycle algorithm) 24 ( 2 ) 時序校正(timing correction) 25 ( 3 ) 血行力學參數之計算與分析 25 ( 4 ) 動脈容積度 28 ( 5 ) 前進波、反射技與反射係數推算 29 ( 6 ) 波傳輸時間的推算 30 ( 7 ) 左心室比率 30 3. 膠體電泳 31 (四) 統計分析 32 三、結果 33 (一) 體重、左心室重、主動脈壓特性的變化 33 (二) 主動脈輸入阻抗頻譜 33 (三) 電泳圖 34 (四) 靜態血管動力的變化 35 (五) 動態血管動力的變化 35 四、討論 36 五、結論 41 六、圖表 42 表一、老化和PM 對於Fisher 344 大鼠的體重、左心室重量、及主動脈壓力的影響。 42 圖一：PM 對老化大鼠主動脈輸入阻抗頻譜的影響。 43 圖二：濾出主動脈輸入阻抗頻譜衍生的脈衝式反應函數曲線。 44 圖三：(A) 受試動物主動脈膠原蛋白 SDS-PAGE 電泳圖 45 圖四： 老化與 PM 對於基礎心率 (HR，圖 A) 47 圖五：老化與 PM 對於主動脈特徵阻抗 (Zc，圖 A) 48 七、參考資料 49 八、附錄 62 | |
| dc.language.iso | zh-TW | |
| dc.subject | 心血管 | zh_TW |
| dc.subject | pyridoxamine | zh_TW |
| dc.subject | 老化 | zh_TW |
| dc.subject | 高度醣化終產物 | zh_TW |
| dc.subject | 阻抗 | zh_TW |
| dc.subject | aging | en |
| dc.subject | advanced glycation end product | en |
| dc.subject | impedance | en |
| dc.subject | pyridoxamine | en |
| dc.subject | cardiovascular | en |
| dc.title | Pyridoxamine 降低膠原蛋白醣化作用，可預防老年 Fisher 344 老鼠主動脈硬化與降低血管阻力 | zh_TW |
| dc.title | Pyridoxamine prevents age-related aortic stiffening and vascular resistance in association with reduced collagen glycation in aged Fisher 344 rats. | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-1 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 吳明修,蔡明憲,王水深,陳益祥 | |
| dc.subject.keyword | 老化,心血管,阻抗,高度醣化終產物,pyridoxamine, | zh_TW |
| dc.subject.keyword | aging,cardiovascular,impedance,advanced glycation end product,pyridoxamine, | en |
| dc.relation.page | 68 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2014-02-10 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 生理學研究所 | zh_TW |
| 顯示於系所單位： | 生理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-103-1.pdf 未授權公開取用 | 9.75 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。